Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 6670

2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy - results of a multicentric experience


Brugiatelli, M.; Holowiecka, B.; Dmoszynska, A.; Krieger, O.; Planinc-Peraica, Ana; Labar, B.; Callea, V.; Morabito, F.; Jakšić, Branimir; Holowiecki, J.; Lutz, D.
2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy - results of a multicentric experience // Annals of hematology, 73 (1996), 2; 79-84 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 6670 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy - results of a multicentric experience

Autori
Brugiatelli, M. ; Holowiecka, B. ; Dmoszynska, A. ; Krieger, O. ; Planinc-Peraica, Ana ; Labar, B. ; Callea, V. ; Morabito, F. ; Jakšić, Branimir ; Holowiecki, J. ; Lutz, D.

Izvornik
Annals of hematology (0939-5555) 73 (1996), 2; 79-84

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
2-CDA ; non Hodgkin's lymphoma ; chronic lymphocytic leukemia ; drug efficacy ; drug toxicity

Sažetak
Among the purine analogs, 2-chlorodeoxyadenosine (2-CDA) is particularly effective for the treatment of hairy cell leukemia and Waldemstrom's macroglobulinemia. Both efficacy and toxicity of 2-CDA were evaluated in previously treated patients affected with chronic lymphoproliferative disorders such as low-grade non-Hodgkin's lymphoma (NHL) and B-cell chronic lymphocytic leukemia (CLL). Thirty cases, mainly refractory, 16 affected with CLL, were included from six centers of the International Society for Chemo-Immunotherapy (IGCI). 2-CDA was administered in a 2 h i.v. infusion for 5-7 days at the standard dose of 0.1 mg/kg/day every 4 weeks. The median number of cycles was 3. Of 30 cases, eight (26.7%) achieved a complete remission (CR), nine (30%) a partial remission (PR), and two (6.7%) a minor response, while five cases (16.6%) did not respond, and six (20%) were considered early deaths. The overall response rate (CR + PR) was 56.7%, with a median response duration of 12 months (range 3-28 +) and a better response in CLL patients. Considering that the majority of patients were heavily pretreated, toxicity was acceptable, with 40% of cases not presenting any toxic effect. The main toxicity consisted in infectious complications. Based on the results of the present study, we confirm that 2-CDA is an effective drug in these lymphoproliferative disorders, suggesting its possible use either alone or in combination, also as first-line therapy.

Izvorni jezik
Engleski

Znanstvena područja
Javno zdravstvo i zdravstvena zaštita



POVEZANOST RADA


Projekti:
108091

Ustanove:
Medicinski fakultet, Zagreb

Profili:

Avatar Url Branimir Jakšić (autor)

Avatar Url Boris Labar (autor)

Avatar Url Ana Planinc-Peraica (autor)


Citiraj ovu publikaciju:

Brugiatelli, M.; Holowiecka, B.; Dmoszynska, A.; Krieger, O.; Planinc-Peraica, Ana; Labar, B.; Callea, V.; Morabito, F.; Jakšić, Branimir; Holowiecki, J.; Lutz, D.
2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy - results of a multicentric experience // Annals of hematology, 73 (1996), 2; 79-84 (međunarodna recenzija, članak, znanstveni)
Brugiatelli, M., Holowiecka, B., Dmoszynska, A., Krieger, O., Planinc-Peraica, A., Labar, B., Callea, V., Morabito, F., Jakšić, B., Holowiecki, J. & Lutz, D. (1996) 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy - results of a multicentric experience. Annals of hematology, 73 (2), 79-84.
@article{article, author = {Brugiatelli, M. and Holowiecka, B. and Dmoszynska, A. and Krieger, O. and Planinc-Peraica, Ana and Labar, B. and Callea, V. and Morabito, F. and Jak\v{s}i\'{c}, Branimir and Holowiecki, J. and Lutz, D.}, year = {1996}, pages = {79-84}, keywords = {2-CDA, non Hodgkin's lymphoma, chronic lymphocytic leukemia, drug efficacy, drug toxicity}, journal = {Annals of hematology}, volume = {73}, number = {2}, issn = {0939-5555}, title = {2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy - results of a multicentric experience}, keyword = {2-CDA, non Hodgkin's lymphoma, chronic lymphocytic leukemia, drug efficacy, drug toxicity} }
@article{article, author = {Brugiatelli, M. and Holowiecka, B. and Dmoszynska, A. and Krieger, O. and Planinc-Peraica, Ana and Labar, B. and Callea, V. and Morabito, F. and Jak\v{s}i\'{c}, Branimir and Holowiecki, J. and Lutz, D.}, year = {1996}, pages = {79-84}, keywords = {2-CDA, non Hodgkin's lymphoma, chronic lymphocytic leukemia, drug efficacy, drug toxicity}, journal = {Annals of hematology}, volume = {73}, number = {2}, issn = {0939-5555}, title = {2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy - results of a multicentric experience}, keyword = {2-CDA, non Hodgkin's lymphoma, chronic lymphocytic leukemia, drug efficacy, drug toxicity} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE





Contrast
Increase Font
Decrease Font
Dyslexic Font